Skip to main content
main-content

01.03.2018 | Cardio-oncology (M Fradley, Section Editor) | Ausgabe 3/2018

Current Treatment Options in Cardiovascular Medicine 3/2018

Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention

Zeitschrift:
Current Treatment Options in Cardiovascular Medicine > Ausgabe 3/2018
Autoren:
MD Dae Hyun Lee, MD Michael G. Fradley
Wichtige Hinweise
This article is part of the Topical Collection on Cardio-oncology

Abstract

Purpose of review

Multiple myeloma treatment regimens consist of proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide), and steroids. In this paper, we will review the pathophysiology and associated cardiotoxicities of the different multiple myeloma therapeutic modalities and present methods to mitigate the development of cardiovascular complications.

Recent findings

Although proteasome inhibitors and immunomodulatory drugs have led to significant improvements in oncologic outcomes, there is increasing evidence of serious cardiovascular side effects which may be exacerbated in the setting of underlying cardiovascular risk factors or disease. Cardiotoxicities include cardiomyopathy and heart failure, accelerated hypertension, arrhythmias, and both arterial and venous thromboembolism.

Summary

Given the frequency of cardiovascular risk factors in multiple myeloma patients as well as the cardiotoxicities associated with the different treatment regimens, it is essential to closely monitor these patients. Collaboration between cardiologists and oncologists is necessary to ensure patients receive optimal cancer treatment while minimizing cardiovascular risk.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2018

Current Treatment Options in Cardiovascular Medicine 3/2018 Zur Ausgabe

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

Spontaneous Coronary Artery Dissection: Diagnosis and Management

Arrhythmia (G Upadhyay, Section Editor)

Ablation Approaches for Ventricular Fibrillation

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

Timing and Outcomes of PCI in the TAVR Era

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise